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Abstract
Background: Stroke and Ischemic Heart Diseases (IHD) are the main cause of premature deaths globally, including
Turkey. There is substantial potential to reduce stroke and IHD mortality burden; particularly by improving diet and
health behaviours at the population level. Our aim is to estimate and compare the potential impact of ischemic
stroke treatment vs population level policies on ischemic stroke and IHD deaths in Turkey if achieved like other
developed countries up to 2022 and 2032.
Methods: We developed a Markov model for the Turkish population aged >35 years. The model follows the
population over a time horizon of 10 and 20 years. We modelled seven policy scenarios: a baseline scenario, three
ischemic stroke treatment improvement scenarios and three population level policy intervention scenarios (based
on target reductions in dietary salt, transfat and unsaturated fat intake, smoking prevalence and increases in fruit
and vegetable consumption). Parameter uncertainty was explored by including probabilistic sensitivity analysis.
Results: In the baseline scenario, we forecast that approximately 655,180 ischemic stroke and IHD deaths (306,500
in men; 348,600 in women) may occur in the age group of 35–94 between 2012 and 2022 in Turkey. Feasible
interventions in population level policies might prevent approximately 108,000 (62,580–326,700) fewer stroke and
IHD deaths. This could result in approximately a 17 % reduction in total stroke and IHD deaths in 2022.
Approximately 32 %, 29 %, 11 % and 6 % of that figure could be attributed to a decreased consumption of transfat,
dietary salt, saturated fats and fall in smoking prevalence and 22 % could be attributed to increased fruit and
vegetable consumption. Feasible improvements in ischemic stroke treatment could prevent approximately 9 %
fewer ischemic stroke and IHD deaths by 2022.
Conclusions: Our modeling study suggests that effective and evidence-based food policies at the population level
could massively contribute to reduction in ischemic stroke and IHD mortality in a decade and deliver bigger gains
compared to healthcare based interventions for primary and secondary prevention.
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Background
Ischemic stroke and ischemic heart disease (IHD) con-
tinue to cause most cardiovascular and circulatory
deaths globally, which mostly contribute to the increas-
ing number of premature deaths, [1]. Stroke accounts
for a substantial proportion of these deaths worldwide,
with being the main cause of 10 % of the deaths and 4 %
of the DALYs (Disability adjusted life years) in 2010, [2].
While some high-income countries show dramatic de-
creases in stroke incidence in the past four decades, in
many low and middle income countries stroke incidence
and number of stroke related deaths and DALYs are still
increasing, [2, 3].
In common with other middle income countries,
stroke is still one of the most common cause of deaths
in Turkey. In 2013, IHD and stroke remained to be the
top two causes of years of life lost (YLLs) as they were
in National Burden of Study in 2000, [4, 5].
Stroke and IHD deaths are eminently preventable and
acute and secondary treatments contribute to reduce mor-
tality, however, prevention from stroke could contribute
to this reduction more. Consumption of a diet with re-
duced sodium, increased portions of fruits and vegetables,
with smoking cessation and with control of diabetes melli-
tus in combination with treatment of hypertension shown
to prevent stroke incidence and deaths, [6]. These kind of
effective interventions may require policy initiatives to
support the individuals to change health behaviours or to
effectively medicate them, [7]. Thus, a better understand-
ing of the effectiveness of policy or other interventions
has been an urgent need to inform ischemic stroke and
IHD prevention strategies.
We, therefore, aimed to model and compare the future
impact of different policy scenarios targeting to improve
ischemic stroke treatment and to improve nutrition at
the population level with policy interventions including
smoking cessation on both ischemic stroke and IHD
deaths for the next two decades.
Methods
The Ischemic Stroke Model is a Microsoft Excel cell-
based Markov model, for Turkish population of 35 years
and over, consisting finite number of health states
reflecting the natural history of ischemic stroke. Markov
Model provides estimates for future burden of CVD
deaths and it can provide information for policy makers
by comparing the outcomes from different intervention
scenarios targeting specific risk factors and treatments
[8, 9]. The model starts in 2012 and runs for 10 and
20 years. We assumed that a close cohort of individuals
is free of ischemic stroke at the start of the simulation
and every year the individuals can move from one health
state to another. The possible pathways between heath
states are shown in Fig. 1.
The main model inputs are population data, incidence
and case-fatality rates of ischemic stroke. The main out-
come is the total number of ischemic stroke and IHD
deaths that will occur over a 10 and 20 years time horizon.
Ethical approval was not required for this model based
study as we made secondary analysis of previously pub-
lished, unidentified and publicly available data.
Data sources
Data for population and prevalence of stroke
We obtained the population data for year 2012 from
Turkish Statistical Institute (TurkStat), [10]. We obtained
prevalence of ischemic stroke from a nationwide study
conducted by Ministry of Health in 2012, [11]. Using
the population and ischemic stroke prevalence data,
we calculated the number of ischemic stroke patients
in total population in 2012. By this way we calculated
the number of cohort population that is free of stroke
at the start year 2012.
Data for incidence of stroke
We modelled the incidence of stroke in Turkey for this
stroke-free population. Since there was no available data for
incidence of stroke in Turkey, we estimated stroke inci-
dence using DISMOD II software [12]. DISMOD II calcu-
lates the incidence by using data on age and gender-specific
stroke prevalence, total population, total mortality rates and
stroke remission rate (assumed to be zero). DISMOD II
software also allows us to input incidence from a similar
population in order to make a better estimation. We there-
fore used incidence from an Iranian stroke cohort study
[13] and finally found an estimate for Turkey.
Data for mortality and case-fatality rates
We obtained number of deaths for age groups 35 to 94
from TurkStat for the year 2012, [10]. The model also
required total Cardiovascular Diseases (CVD) deaths data
with the ICD 10 codes from I00 to I99 which we also
obtained from TurkStat database for year 2012. The case
fatality rates of ischemic stroke (both minor and major)
were calculated by analyzing the hospital based Aegean
Stroke Registry database with Kaplan-Meier Method.
Aegean Stroke Registry was used with the collaboration of
researchers of Egean University Hospital [14, 15]. All the
input data were specified for age and sex.
Intervention scenarios
We modelled seven scenarios: a baseline scenario, three
medical treatment scenarios and three population level
prevention scenarios.
For the baseline scenario we assumed no change will
happen during 10 and 20 years in the present uptake
rates of medical therapies or population level uptakes of
nutrients and population smoking prevalence.
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For optimal scenarios to prevent ischemic stroke and
heart diseases, either with medical treatment or preven-
tetive policies, we first simulated the achievements of
more developed countries as the best scenario target
[16–22]. After we were clear about the optimal scenario
standards; we simulated a modest improvement in treat-
ments and interventions; based on expert opinions (car-
diologist and neurologist) as a standard local evidence
was not available. We then calculated a feasible scenario,
half way between the optimal and conservative ones.
Medical treatment scenarios
(a) an optimal scenario; We simulated an increase in
the uptake levels that are already reached in more
developed countries, using as an an exemplar
country, the Netherlands [16, 17].
(b) a conservative scenario; We assumed a modest
10 % relative increase in the current uptake levels.
(c) a feasible scenario; We simulated a more realistic
change, halfway between the current situation and
the optimistic scenario.
The simulated scenarios for the uptake rates of med-
ical treatments can be seen in Table 1.
Population level food policy scenarios
In optimal scenario we assumed improvements already
achieved in exemplar countries. A salt intake reduction
of 30 % (as in Finland and Japan), [18, 19], which we
simulated as a reduction of 5 g/day from the current salt
consumption in Turkey, (14.8 g/day), [23], a 15 % de-
crease in the prevalence of smoking (Australia and
California), [20, 21]. and an absolute decrease of 5 % in
energy from saturated fats (Finland), [22]. In the conser-
vative scenario we assumed a small decrease (1 g/day) in
salt intake, and 0.5 % decrease in energy from transfat
and 1 % from saturated fats (replacing it with energy
from mono—and polyunsaturates), a modest 5 % de-
crease in the prevalence of smoking. Finally, in the feas-
ible scenario we simulated reductions between the
conservative and optimistic ones (Table 2).















Thrombolysis 0,01 0,011 0,05 0,13
Aspirin 0,50 0,55 0,70 0,85
Stroke unit 0,00 0,01 0,40 0,85
Secondary prevention
Aspirin 0,26 0,29 0,50 0,81
Statin 0,48 0,53 0,70 0,80a
Warfarin 0,14 0,20 0,40 0,50a
BP control 0,35 0,39 0,50 0,62
Smoking cessation 0,30 0,33 0,50 0,60a
Primary prevention
BP control 0,07 0,08 0,10 0,12a
HbA1c control 0,49 0,54 0,70 0,80a
Smoking cessation 0,04 0,07 0,10 0,13
Warfarin 0,30 0,33 0,50 0,78
aAssuming 10 % relative increase in scenarios
Fig. 1 The relations of health states in ischemic stroke model. TIA: Transient Ischemic Attack. CVD: Cardiovascular Disease
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Modelling policy effectiveness and its impact in mortality
The model applies the relative risk reduction (RRR)
quantified in previous randomised controlled trials and
meta-analyses based on overseas studies. The model cal-
culates the reductions in ischemic stroke and heart dis-
ease deaths by multiplying the transition probabilities
with policy effectiveness. Table 3 shows the relative risk
reductions for ischemic stroke and IHD deaths applied
for each intervention scenario.
Ischemic heart disease deaths were classified under
the ICD 10 codes I20–I25. An example of the calcu-
lation method used for calculating the deaths pre-
vented or postponed (DPPs) with a population level
policy scenario is available in Additional file 1, section
1.5. We modelled all the intervention scenarios to
calculate the total number CVD deaths (ischemic
stroke and IHD deaths) that could be prevented or
postponed under each specific scenario, compared to
the baseline scenario.
Sensitivity analysis
We implemented sensitivity analysis using the Excel
add-in Ersatz software which allows Monte Carlo simu-
lation, [24]. This allowed us to calculate 95 % uncer-
tainty intervals (95 % UI) for prevented or postponed
deaths, based on 1000 draws from specified probabilistic
distributions for the model input variables.
Further details on methods and data sources are pro-
vided in Additional file 1.
Results
In the baseline scenario, we forecast that approximately
655,180 ischemic stroke and IHD deaths (306,500 in
men; 348,600 in women) may occur in the age group of
35–94 between 2012 and 2022 and 1,150,000 ischemic
stroke and IHD deaths (544,720 in men; 650,230 in
women) between 2012 and 2032 in Turkey.
Figure 2 shows the estimated number of the ischemic
stroke and IHD deaths that could be prevented or
Table 2 Scenarios for population level policy interventions
Scenarios Conservative Feasible Optimal
Reduction in Salt Intake (g/day) 1 3 5
Reduction in Trans-Fat Intake (%) 0.5 1 2
Reduction in Saturated Fat (%)
(replaced by polyunsaturates)
1 3 5
Increase in Fruit And Vegetable
Intake (portion/day)
1 2 3
Reduction in Smoking Prevalence (%) 5 10 15
Table 3 Relative risk reductions for CVD deaths from previous studies for intervention scenarios
Intervention Relative risk reduction (RRR) Description
Thrombolysis Treatment 11 % (95 % CI: 5–16) RRR for stroke death or dependency if applied within 4.5 h [48]
Aspirin Treatment 2,6 % (95 % CI: 0.4–4) RRR for stroke death or dependency if treatment is 160–300 mg once daily,
started within 48 h of onset [49]
Stroke Unit 6,1 % (95 % CI:0,0009–11) RRR for stroke death or dependency [50]
Aspirin Treatment for secondary
prevention
3 % (95 % CI: 6–19) RRR for vascular events (stroke or IHD death) if treatment is at any dose above
30 mg daily [51]
Statin Treatment 12 % (95 % CI: (-1)–21) RRR for recurrent stroke if LDL reduces by 1 mmol/L [52]
Warfarin Treatment for secondary
prevention
61 % (95 % CI: 37–75) RRR for recurrent stroke or systemic embolism among stroke patients with
Transient Ischemic Attack or minor stroke due to atrial fibrillation when
treated with anticougulation [53]
BP Control for secondary prevention 34 % (95 % CI: 21–44) RRR for stroke based on BP reduction of 4–25 mmHG systolic or 3–13 Hg diastolic [54]
Smoking Cessation 48 % (95 % CI: 29–57) RRR for stroke death or dependency [16]
BP Control for primary prevention 46 % (95 % CI: 35–55) RRR based on BP reduction 5 mmHg. This reduces the risk of stroke by an estimated
34 % and ischemic heart disease by 21 % from any pre-treatment level [55]
HbA1C Control 7 % (95 % CI: 4–19) RRR for stroke based on 0,9 % HbA1C reduction [56]
Warfarin Treatment for primary
prevention
64 % (95 % CI: 49–74) RRR for stroke based on a meta-analysis with twenty-nine trials, adjusted-dose
warfarin reduced stroke by 64 % [57]
Salt Reduction 17 % (95 % CI:6–43) RRR for stroke by 5gr change in daily salt intake [58]
Transfat Reduction 12 % (95 % CI:5.5–18.5) RRR by replacing 1 % of energy from trans-fat with unsaturated fats for coronary
heart disease [59] We assumed half effect for stroke
Saturated Fat Reduction 13 % (95 % CI: 1–6) RRR by replacing 5 % of energy from saturated fat with Polyunsaturated fats
(PUFAs) for coronary heart disease [60] We assumed half effect for stroke
Fruit and Vegetables Intake 4 % (95 % CI:3–8) RRR for stroke by change in 1 unit of fruit and vegetables [61]
Smoking Prevalence Reduction 1.9 % (95 % CI:1.5–2.3) RRR by change in 1 % prevalence of smoking [62]
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postponed by achievement of conservative, feasible or
optimal scenarios of medical treatment and population
level policy improvements in Turkey for year 2022.
Optimal scenario
Optimal improvements in acute treatment, secondary
and primary prevention of stroke could result in ap-
proximately 89,810 fewer ischemic stroke and IHD
deaths (74,725–97,432) in 10 years. This would represent
a 13 % reduction in forecasted ischemic stroke and IHD
deaths up to year 2022 and continuing up to 2032 in
Turkey.
A daily reduction of 5 g/day in salt intake could result
in approximately 51,975 fewer ischemic stroke and IHD
deaths (range: 6,257–283,596). A reduction of 2 % in
total energy from trans fats might generate approxi-
mately 47,528 fewer deaths (range:22,581–125,960) while
a reduction of 5 % in total energy from saturated fats
could result in approximately 39,563 fewer deaths
(range:12,924–126,526). Additional 3 portions of fruit
and vegetables daily consumption could result in approxi-
mately 35,893 fewer deaths (range:7,480–183,191) and a
decrease of 15 % in the smoking prevelance of total
population in 10 years might result 10,739 (range:7,551–
15,118) fewer deaths up to year 2022 and continuing up
to 2032 in Turkey.
Conservative scenario
Slight improvements in acute treatment, secondary and
primary prevention of ischemic stroke; assuming 10 %
relative increase in the present uptake levels of medical
therapies could result in approximately 49,885 fewer
ischemic stroke and IHD deaths (45,757–61,714) in
10 years. This would represent a 7 % reduction from the
total forecasted stroke and IHD deaths up to 2022 and a
9 % reduction up to 2032 in Turkey.
Reducing the total energy from trans fats by 0.5 % and
from saturated fat by 1 %, reducing salt consumption by
1 g per day, and increasing fruit and vegetable intake by
1 portion per day and 5 % decrease in smoking preva-
lence could result in approximately 58,962 fewer ische-
mic stroke and IHD deaths (minimum: 30,786
maximum: 119,990) in 10 years and 103,993 fewer
deaths (54,288–212,091) in 20 years. This would repre-
sent an 11 % reduction in the total forecasted stroke and
IHD deaths up to year 2022 and continuing up to 2032
in Turkey.
Feasible scenario
Table 4 shows the estimated reductions in number of is-
chemic stroke and IHD deaths with achievement of a
feasible scenario in acute, secondary and primary levels
of ischemic stroke treatment.
Fig. 2 Reduction in number of deaths by achievement of improvements in Turkey up to 2022. CVD: Cardiovascular Disease
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Achievement of improvements in treatment of ische-
mic stroke could result in approximately a 9 % reduction
in total forecasted ischemic stroke and IHD deaths up to
year 2022.
Table 5 shows the estimated reduction in number of
ischemic stroke and IHD deaths by achievement of a
feasible scenario (simulating reductions in dietary salt by
3 g/day trans-fat by 1 % of daily energy intake saturated
fat by 3 % of daily energy intake increasing fruit and
vegetable intake by 2 portions/day and 10 % decrease in
smoking prevalence in the population). These population
level policy interventions could result in approximately a
17 % reduction in total forecasted ischemic stroke and
IHD deaths up to year 2022 and continuing up to 2032.
Dıscussıon
This modelling study estimates the future impact of pos-
sible population level policy interventions and ischemic
stroke treatment scenarios on ischemic stroke and IHD
deaths in Turkey. Approximately 655000 ischemic stroke
and IHD deaths may occur between 2012 and 2022 in
the base scenario. The model estimates suggest that even
with conservative changes in food policy approximately
60000 deaths can be prevented or postponed in 10 years
time. Primary prevention and food policies especially
feasible reductions in transfat and salt made the highest
contribution to this health gain whereas acute and
chronic care for ischemic stroke with contributing
additional benefits will be unsufficient to significantly
impact on future burden of stroke in Turkey.
Many of the interventions to prevent deaths from IHD
and ischemic stroke constitute medical treatments and
the “high-risk approach”. However there could be
massive health gains by prevention of IHD and ischemc
stroke deaths if population level policies were success-
fully implemented in Turkey.
Our study suggests that thousands of deaths could be
prevented with transfat reduction at population level. This
could be achieved by public campaigns food labelling and
legislative policies [25]. There are exampler countries who
imposed legislation on food manufacturers to limit their
population’s intake of trans-fats. For example in 2003
Denmark set an upper limit for artificial trans fat levels in
foods effectively banning partially hydrogenated oils. In
the following years New York and Switzerland introduced
legislation to limit trans fat, [26, 27]. In both Denmark
and New York legislation has effectively eliminated indus-
trial transfats; for example in New York restaurants the
prevalence of use of industrial transfats has declined from
50 % to less than 2 % [28, 29]. Similarly in the UK while
transfat accounted for 1.1 % of food energy in 2000 this
reduced to 0.8 % of food energy in 2010 with implementa-
tion of successful legislative strategies [30]. There are also
successful examples of policy interventions on industrial
food labelling. In 2006 introduction of mandatory trans fat
labelling in US prompted reformulation and many
Table 4 Reduction in number of deaths with achievement of feasible treatment interventions in Turkey
2022 2032
Men Women Men Women
N (min-max) % N (min-max) % N (min-max) % N (min-max) %
Acute Stroke treatment 290 (97–2310) 1.1 975 (385–2700) 2.0 1030 (345–890) 2.0 2160 (725–6425) 2.4
Secondary Prevention 7310 (5920–15930) 28.2 19520 (15945–35495) 39.0 27620 (22430–57335) 53.0 51280 (42165–91435) 58.0
Primary prevention 18260 (15590–20505) 70.6 29620 (25855–33095) 59.1 23080 (20570–26250) 45.0 34940 (31115–40090) 39.6
Total 25860 (22640–32415) 100.0 50115 (38900–64635) 100.0 51730 (47995–80115) 100.0 88380 (76960–143020) 100.0
Table 5 Reduction in number of deaths with achievement of feasible population level policy interventions in Turkey
Policy Options 2022 2032
Men Women Men Women
N (min-max) % N (min-max) % N (min-max) % N (min-max) %
Reduction in Salt Intake 16670 (1300–105490) 29.0 14220 (2340–80580) 28.0 27390 (2130–177990) 30.0 23245 (3820–133140) 28.0
Reduction in Transfat
Intake
18680 (12995–35170) 32.0 16090 (5730–37800) 32.0 24790 (14920–53655) 28.0 26320 (9360–62030) 32.0
Reduction in Saturated
Fat Intake
6340 (2240–19970) 11.0 5395 (1905–17050) 11.0 10380 (3665–32850) 11.0 8800 (3110–27885) 11.0
Increasing Fruit &
Vegetables
13050 (2825–44075) 22.0 10780 (1880–43140) 22.0 21415 (4630–72990) 24.0 18120 (3150–73255) 22.0
Reduction in Smoking
Prevalence
3640 (2535–5075) 6.0 3490 (2580–5009) 7.0 6475 (4510–9040) 7.0 6100 (4510–8760) 7.0
Total 58370 (25000–114695) 100.0 49980 (32590–124140) 100.0 90450 (44720–205545) 100.0 82580 (57780–218130) 100.0
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products are now labelled as free from transfats [25]. Al-
though there have been discussions on effectiveness of
transfat reduction strategies for example suggesting that
legislative strategies have been more successful than label-
ling or education [28, 29] the findings of a review with
data from developed countries show that the policies in-
troduced to decrease transfat levels in food supply have
been effective regardless of the intervention employed
[31]. However there is sparse evidence for low and middle
income countries on effectiveness of these policy strategies
responses and health outcomes. Furthermore important in-
equalities exist with high consumption of trans fats in dis-
advantaged groups thus benefits in deprived communities
might be larger [32]. In Turkey Turkish Ministry of Health
has recently established strategic plans on transfat labeling
and reformulation for the year 2017, [33]. Our findings
show that the health gains of these actions will be
massive in Turkey as a middle income country if ef-
fectively implemented.
Reduction of salt in populations has been a prior con-
cern for prevention of cardiovascular diseases including
IHD and ischemic stroke. The WHO Member States
agreed on a voluntary global target for a 30 % relative re-
duction in mean population intake of salt with the aim
of achieving a target of less than 5 g per day by 2025.
Many countries including Japan UK Finland and
Portugal have reduced population-wide salt intake in the
recent years through a combination of regulations on
the salt content in processed foods labeling of processed
and prepared foods public education and engagement
with the food industry [34]. In the UK for example salt
reduction strategy started in 2004 and the adult daily salt
intake decreased from 9.5 g/day to 8.6 g/day by May
2008 [30]. This was a 10 % population-reduction in salt
achieved over 4 years without reduction in sales of the
products and without consumer complaints about taste
[35]. In Finland and Japan 6 g/day reduction was
achieved with specific legislation [34]. Likewise in most
developed countries a reduction in salt intake could be
achieved by reduction in the amount of salt added to
food by the industry. However in some countries public
health campaigns might be needed to raise awareness of
population where most of the salt comes from salt added
during cooking [34]. In Turkey for example where 30 %
of daily salt consumption comes from bread a 3 gr/day
salt reduction (from 18gr/day to 15gr/day) was achieved
between 2008 and 2012 both with health campaings and
legislation on the amount of salt in bread [23]. Our esti-
mates suggest that with continuation of the achievements
in salt reduction at population level even with conserva-
tive reductions thousands of IHD and ischemic stroke
deaths could be saved in the following two decades.
Our study also suggests that substantial number of
IHD and ischemic stroke deaths could be prevented by
increasing fruit and vegetable consumption at popula-
tion level. Although Turkey produces and exports fruit
and vegetable the consumption of fruit and vegetable
shows a decreasing trend [36] and dietary patterns differ
substantially between regions and income groups. In-
come level and lack of knowledge about healthy nutri-
tion are the main determinants of nutrition patterns in
Turkey, [37]. Therefore for low-income groups which
suffer the highest burden of IHD and stroke the benefit
might even be higher with an increase in daily consump-
tion of fruit and vegetables.
Comparison with other modeling studies
In two recent modelling studies in the UK and Ireland
substantial burden of cardiovascular disease (CVD)
deaths might be avoided as a result of changes in average
population dietary intakes. They used IMPACT Food
Policy Model which had a similar study design to our
modelling study [38] [39]. Similar to our estimate of
32 % (the highest) contribution of decrease in trans-fat
consumption to the fall in ischemic stroke and IHD
deaths O’Keeffee et al estimated the greatest potential
impact (28 %) on fall in CVD deaths with a decrease in
trans fat consumption followed by impact of saturated
fat (22 %) dietary salt (23 %) and increased fruit and
vegetable consumption (26 %) in Ireland [38]. Conserva-
tive scenarios in food policy could result in a 10 % over-
all reduction in CVD mortality in Ireland and 8 %
reduction in UK [39] very similar to our findings for
Turkey using a different modelling approach. Modest re-
duction in dietary salt could substantially reduce cardio-
vascular events in other modeling studies similar to our
model estimates for Turkish population. Reduction of
salt of approximately 2 g/day in Argentina was projected
to result in 2.7 % decrease in total stroke mortality in
10 years [40]. In UK reduction of 3 g/day salt would re-
sult with 2 % decrease in risk reduction in CVD events
with savings worth at least £40 m a year [32].
Strenghts and limitations of the study
Our study has some strengths. This is the first modelling
study on ischemic stroke mortality in Turkey based on
available national population-based data. The model is
extendable to other settings and populations. We made
transparent assumptions with a clear justification. For
example as we did not have some of the data that the
model required for medical treatment uptake rates and
interventions at the population-level we based our up-
takes rates from the Netherlands supplemented with ex-
pert opinion (listed in Additional file 1: Table S1)
Furthermore we used DISMOD II software to estimate
stroke incidence that is consistent with prevalence and
mortality estimates for the Turkish population. Finally
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we conducted probabilistic sensitivity analyses to explore
the role of uncertainity of model parameters.
Our study also has some limitations. We assumed that
risk factor effects were independent which could result
in an overestimate of the number of prevented deaths
for each policy. Furthermore our model assume that
food policies homogeneously effect the entire population
and we simulated similar food policy targets across all
age groups regardless of morbidity and the socioeco-
nomic variation in Turkey. The model was based on
ischemic stroke incidence and number of prevented
deaths however the benefit of the people already have
non-fatal stroke could have been taken into consider-
ation. Additionally we did not consider the lag between
improvements in medical treatments and risk factors
changes and corresponding decreases in IHD and ische-
mic stroke mortality. However there is substantial evi-
dence suggesting that declines in mortality can happen
rapidly after individual or population-wide changes in
diet or smoking [41].
Conclusıons
The stroke and cardiovascular disease burden like other
low and middle income countries is increasing in
Turkey. This public health epidemic requires immediate
action. Our analysis suggests that effective and evidence-
based food policies at the population level could mas-
sively contribute through a 20 % reduction in ischemic
stroke and IHD mortality in a decade and deliver bigger
gains compared to healthcare based interventions for
primary and secondary prevention. Results of previous
modelling studies [42, 43] for prevention of cardiovascu-
lar diseases have been utilising by the governments and
WHO [44, 45]. Turkish Ministry of Health also has pol-
icy documents and action plans to reduce the burden of
noncommunicable diseases with effective prevention at
national level [46, 47]. We particularly used these targets
for simulation of scenarios for the next 10 years. Our
modelling study can be a useful tool to explore potential
benefits of implementing certain strategies for prevention
of ischemic stroke and heart diseases in the future. Further
studies that include economic analysis of different inter-
ventions are needed to compare the cost effectiveness
of future scenarios in order to target and implement
the best interventions.
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